ECSP11010830A - Derivados de heteroarilo como inhibidores de dgat1 - Google Patents

Derivados de heteroarilo como inhibidores de dgat1

Info

Publication number
ECSP11010830A
ECSP11010830A EC2011010830A ECSP11010830A ECSP11010830A EC SP11010830 A ECSP11010830 A EC SP11010830A EC 2011010830 A EC2011010830 A EC 2011010830A EC SP11010830 A ECSP11010830 A EC SP11010830A EC SP11010830 A ECSP11010830 A EC SP11010830A
Authority
EC
Ecuador
Prior art keywords
heteroarilo
derivatives
treatment
dgat1 inhibitors
disorders
Prior art date
Application number
EC2011010830A
Other languages
English (en)
Inventor
Cornelia Jutta Forster
Bin Wang
Katsumasa Nakajima
Young-Shin Kwak
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41136646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010830(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11010830A publication Critical patent/ECSP11010830A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a los compuestos de la fórmula (I), en donde A es un heteroarilo opcionalmente sustituido, útiles para el tratamiento de los trastornos mediados por acil-transferasa de acil-CoA-diacil-glicerol 1 (DGAT1), por ejemplo, trastornos metabólicos. La invención también proporciona métodos para el tratamiento de estos trastornos, y los compuestos y composiciones etc. para su tratamiento.
EC2011010830A 2008-07-15 2011-02-15 Derivados de heteroarilo como inhibidores de dgat1 ECSP11010830A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8091308P 2008-07-15 2008-07-15

Publications (1)

Publication Number Publication Date
ECSP11010830A true ECSP11010830A (es) 2011-03-31

Family

ID=41136646

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010830A ECSP11010830A (es) 2008-07-15 2011-02-15 Derivados de heteroarilo como inhibidores de dgat1

Country Status (23)

Country Link
US (1) US8703761B2 (es)
EP (4) EP2349484A2 (es)
JP (1) JP5401544B2 (es)
KR (1) KR20110028661A (es)
CN (1) CN102119047B (es)
AR (1) AR072559A1 (es)
AU (1) AU2009272826A1 (es)
BR (1) BRPI0916216A2 (es)
CA (1) CA2731097A1 (es)
CL (1) CL2011000087A1 (es)
CO (1) CO6341581A2 (es)
CR (1) CR20110013A (es)
EA (1) EA201100189A1 (es)
EC (1) ECSP11010830A (es)
IL (1) IL210292A0 (es)
MA (1) MA32558B1 (es)
MX (1) MX2011000628A (es)
NZ (1) NZ590285A (es)
PE (1) PE20110105A1 (es)
SV (1) SV2011003809A (es)
TW (1) TW201006832A (es)
UY (1) UY31986A (es)
WO (1) WO2010007046A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP2011529072A (ja) * 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
JP2012517997A (ja) * 2009-02-17 2012-08-09 Ｍｓｄ株式会社 １，４−ベンゾジアゼピン−２−オン誘導体
JP6099753B2 (ja) * 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
TWI691486B (zh) 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
US10881649B2 (en) 2017-07-27 2021-01-05 Toray Industries, Inc. Therapeutic agent or preventive agent for alopecia areata
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
US11497752B2 (en) * 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113645971B (zh) * 2019-01-29 2024-10-18 福宏治疗公司 化合物及其用途
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
CN115484948A (zh) * 2020-01-29 2022-12-16 福宏治疗公司 化合物及其用途
JP7693688B2 (ja) * 2020-01-29 2025-06-17 フォグホーン セラピューティクス インコーポレイテッド 化合物およびその使用
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
TWD226926S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
TWD226927S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
WO2024191268A1 (ko) * 2023-03-15 2024-09-19 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물
KR20260037054A (ko) * 2024-09-09 2026-03-17 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526938A (en) * 1974-12-19 1978-10-04 Shell Int Research Derivatives of n-phenyl-n-aroylalanine and herbicidal compositions containing them
CA1160234A (en) * 1980-10-30 1984-01-10 Masahiko Nagakura Thiadiazole derivatives and process for preparing same
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AU2847200A (en) * 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
CN1436175A (zh) * 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ－蛋白生产抑制剂的环状内酰胺
EP1335914A1 (en) * 2000-10-26 2003-08-20 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
CA2448737C (en) * 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
MXPA05003432A (es) 2002-10-09 2005-07-05 Pfizer Prod Inc Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
JP2006504796A (ja) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
JP2005206492A (ja) * 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AR049333A1 (es) * 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP4819686B2 (ja) 2004-09-24 2011-11-24 ミドリ安全株式会社 靴底及び靴
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
JP2008540485A (ja) * 2005-05-10 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ジアシルグリセロールアシルトランスフェラーゼ阻害剤
WO2006127550A1 (en) * 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
KR20080063865A (ko) * 2005-11-28 2008-07-07 에프. 호프만-라 로슈 아게 다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
EP2007716A1 (en) * 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
TW200827340A (en) * 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
JP2008133218A (ja) * 2006-11-28 2008-06-12 Hokko Chem Ind Co Ltd フェノキシ酪酸アミド誘導体および除草剤
US8957063B2 (en) 2008-02-21 2015-02-17 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the CB2 receptor

Also Published As

Publication number Publication date
CO6341581A2 (es) 2011-11-21
PE20110105A1 (es) 2011-02-25
US20100022513A1 (en) 2010-01-28
SV2011003809A (es) 2011-07-05
JP2011528016A (ja) 2011-11-10
MX2011000628A (es) 2011-02-25
US8703761B2 (en) 2014-04-22
EP2559455A1 (en) 2013-02-20
BRPI0916216A2 (pt) 2018-03-13
CR20110013A (es) 2011-02-11
CN102119047A (zh) 2011-07-06
IL210292A0 (en) 2011-03-31
EP2548618A3 (en) 2013-02-27
EP2548618A2 (en) 2013-01-23
WO2010007046A2 (en) 2010-01-21
CA2731097A1 (en) 2010-01-21
NZ590285A (en) 2012-10-26
TW201006832A (en) 2010-02-16
AU2009272826A1 (en) 2010-01-21
CN102119047B (zh) 2014-09-24
EP2349484A2 (en) 2011-08-03
WO2010007046A3 (en) 2010-07-22
CL2011000087A1 (es) 2011-07-01
JP5401544B2 (ja) 2014-01-29
MA32558B1 (fr) 2011-08-01
EA201100189A1 (ru) 2011-08-30
EP2380631A1 (en) 2011-10-26
AR072559A1 (es) 2010-09-08
UY31986A (es) 2010-02-26
KR20110028661A (ko) 2011-03-21

Similar Documents

Publication Publication Date Title
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
EA201100447A1 (ru) Органические соединения
NI201000198A (es) Compuestos triazina como inhibidores mtor y quinasa p13.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
BR112015004111A2 (pt) novos derivados bicíclicos
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
BR122019015876B8 (pt) compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos
EA201200741A1 (ru) Способ получения этексилата дабигатрана
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
MA32508B1 (fr) Composes organiques
MX2012012527A (es) Compuestos quimicos.
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
EA200900945A1 (ru) Новый способ синтеза агомелатина
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA200900946A1 (ru) Новый способ синтеза агомелатина
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
EA200900943A1 (ru) Новый способ синтеза агомелатина